<DOC>
	<DOC>NCT00621582</DOC>
	<brief_summary>The objective of the present Post Marketing Surveillance Study (PMS) study is to evaluate safety and effectiveness of tiotropium bromide (Spiriva®) 18 µg once daily in 5,000 patients with COPD of varying severities over 8 weeks.</brief_summary>
	<brief_title>Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities</brief_title>
	<detailed_description>Study Design:</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Incl. Criteria Patients with clinical diagnosis of stable Chronic Obstructive Pulmonary Disease (COPD) according to definition of China COPD guideline. Patients over 40 years old Patient with history of hypersensitivity to tiotropium bromide, atropine and/or its derivant, i.e. ipratropium, or any component of Spiriva® Patient with known narrowangle glaucoma Patient with known symptomatic prostatic hyperplasia and/or bladderneck obstruction Patient with known moderate to severe renal impairment (i.e.,creatinin clearance&lt;=50ml/min) Pregnant or nursing women Patient with any significant disease other than COPD which would exclude him/her from participating in the study Patients with any conditions listed in [special precautions], [drug interactions], and [contraindication] of Spiriva® China package insert Patients with signed informed consent of any other study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>